Bayer says Nexavar fails in breast cancer study




Whatsapp News

FRANKFURT – German drugmaker Bayer said a Phase III of cancer drug Nexavar in patients advanced breast cancer did not meet its primary endpoint of delaying the progression of the .

The , called Resilience, evaluated Nexavar in combination chemotherapeutic agent capecitabine, in HER2-negative breast cancer.

[eap_ad_1]

Oral drug Nexavar, which Bayer is developing jointly Amgen, is approved for against certain types of liver, kidney and thyroid cancer.

details are expected be presented at an upcoming scientific . (Reuters)

[eap_ad_4]